番茄社区app

Significant decrease in rate of photoreceptor loss in two randomized trials

Consistent vision effect with complement C1q inhibitor, despite no effect on lesion size

Some degree of improvement in disease status in 70% of patients treated with tarcocimab

All but one patient with nonproliferative diabetic retinopathy had stable disease or improvement

Improved visual acuity, retinal thickness at 6 and 12 weeks, but treatment burden questioned

Other studies report fewer reoperations with combo eye surgery and vision risk with shingles

Tarcocimab noninferior to aflibercept while cutting treatment burden in half

Five-year follow-up shows significantly less annual visual field progression with the stent

Twice as many patients met IOP goals with TIGS, but confounders complicated data analysis

Slowing of geographic atrophy at 1 and 2 years with pegcetacoplan, avacincaptad pegol

Dosing 8 mg every 12 or 16 weeks for DME, AMD matches results with 2 mg every 8 weeks

Maria Aaron, MD, previews the programs and studies at the 2022 meeting in Chicago

Device lowers eye pressure by promoting fluid flow through Schlemm's canal

Indian eye doctors also warn of dangerous infections associated with steroids, diabetes